Literature DB >> 7775872

Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth.

A Abe1, N S Radin, J A Shayman, L L Wotring, R E Zipkin, R Sivakumar, J M Ruggieri, K G Carson, B Ganem.   

Abstract

Analogs and homologs of PDMP were synthesized, based on its structure (D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol). This compound had previously been found to block the synthesis of GlcCer (glucosylceramide). Increasing the acyl chain length from 10 to 16 carbon atoms greatly enhanced the efficacy of the enzyme inhibitor, as did the use of a less polar cyclic amine, especially a pyrrolidine instead of a morpholine ring. Replacement of the phenyl ring by a chain corresponding to sphingosine also yielded a strongly inhibitory material. By using a chiral synthetic route, we showed that the isomers active against GlcCer synthase had the R,R-(D-threo)-configuration. However, strong inhibition of the growth of human cancer cells in plastico was produced by both the threo and erythro racemic compounds, showing involvement of an additional factor (beyond simple depletion of cell glycosphingolipids by blockage of GlcCer synthesis). The growth arresting effects could be correlated with increases in cellular ceramide and diglyceride levels. The aliphatic pyrrolidino compound was strongly inhibitory toward the glucosyltransferase and produced almost complete depletion of glycolipids, but did not inhibit growth or cause an accumulation of ceramide. Attempts were made to see whether the differences in growth effects could be attributed to the influence of the inhibitors on related enzymes (ceramide and sphingomyelin synthase and ceramidase and sphingomyelinase). While some stimulation of enzyme activity was noted, particularly at high inhibitor concentrations (50 microM), these findings did not explain the differing effects of the different inhibitors. The best inhibitors of GlcCer synthase compared favorably in efficacy with some cancer chemotherapeutic drugs in current use when tested with a battery of human cancer cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7775872

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  40 in total

1.  GD3 expression in CHO-K1 cells increases growth rate, induces morphological changes, and affects cell-substrate interactions.

Authors:  Jose L Daniotti; Adolfo R Zurita; Vera M T Trindade; Hugo J F Maccioni
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

Review 2.  Group XV phospholipase A₂, a lysosomal phospholipase A₂.

Authors:  James A Shayman; Robert Kelly; Jessica Kollmeyer; Yongqun He; Akira Abe
Journal:  Prog Lipid Res       Date:  2010-11-11       Impact factor: 16.195

3.  Human glycolipid transfer protein gene (GLTP) expression is regulated by Sp1 and Sp3: involvement of the bioactive sphingolipid ceramide.

Authors:  Xianqiong Zou; Yongguang Gao; Vivian R Ruvolo; Tawnya L Gardner; Peter P Ruvolo; Rhoderick E Brown
Journal:  J Biol Chem       Date:  2010-10-25       Impact factor: 5.157

4.  Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.

Authors:  Alicja Bielawska; Jacek Bielawski; Zdzislaw M Szulc; Nalini Mayroo; Xiang Liu; AiPing Bai; Saeed Elojeimy; Barbara Rembiesa; Jason Pierce; James S Norris; Yusuf A Hannun
Journal:  Bioorg Med Chem       Date:  2007-08-24       Impact factor: 3.641

5.  Coxsackievirus A24 variant uses sialic acid-containing O-linked glycoconjugates as cellular receptors on human ocular cells.

Authors:  Nitesh Mistry; Hirotoshi Inoue; Fariba Jamshidi; Rickard J Storm; M Steven Oberste; Niklas Arnberg
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

6.  Sialylation regulates brain structure and function.

Authors:  Seung-Wan Yoo; Mary G Motari; Keiichiro Susuki; Jillian Prendergast; Andrea Mountney; Andres Hurtado; Ronald L Schnaar
Journal:  FASEB J       Date:  2015-04-06       Impact factor: 5.191

Review 7.  Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.

Authors:  Samy A F Morad; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2015-05-09

8.  Histidine-193 of rat glucosylceramide synthase resides in a UDP-glucose- and inhibitor (D-threo-1-phenyl-2-decanoylamino-3-morpholinopropan-1-ol)-binding region: a biochemical and mutational study.

Authors:  K Wu; D L Marks; R Watanabe; P Paul; N Rajan; R E Pagano
Journal:  Biochem J       Date:  1999-07-15       Impact factor: 3.857

Review 9.  A turn in the road: How studies on the pharmacology of glucosylceramide synthase inhibitors led to the identification of a lysosomal phospholipase A2 with ceramide transacylase activity.

Authors:  James A Shayman; Akira Abe; Miki Hiraoka
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

10.  E-selectin receptors on human leukocytes.

Authors:  Leonardo Nimrichter; Monica M Burdick; Kazuhiro Aoki; Wouter Laroy; Mark A Fierro; Sherry A Hudson; Christopher E Von Seggern; Robert J Cotter; Bruce S Bochner; Michael Tiemeyer; Konstantinos Konstantopoulos; Ronald L Schnaar
Journal:  Blood       Date:  2008-06-25       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.